Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Community Acquired Pneumonia Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Community Acquired Pneumonia Overview | 10 | 1 |
| Community Acquired Pneumonia Therapeutics under Development by Companies | 11 | 1 |
| Community Acquired Pneumonia Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Community Acquired Pneumonia Products under Development by Companies | 15 | 2 |
| Community Acquired Pneumonia Companies Involved in Therapeutics Development | 17 | 16 |
| Aridis Pharmaceuticals LLC | 17 | 1 |
| BioAegis Therapeutics, Inc. | 18 | 1 |
| Biotest AG | 19 | 1 |
| C10 Pharma AS | 20 | 1 |
| InflaRx GmbH | 21 | 1 |
| ioGenetics, Inc. | 22 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 23 | 1 |
| Lascco SA | 24 | 1 |
| Melinta Therapeutics, Inc | 25 | 1 |
| Merck &Co., Inc. | 26 | 1 |
| Nabriva Therapeutics AG | 27 | 1 |
| Paratek Pharmaceuticals, Inc. | 28 | 1 |
| TaiGen Biotechnology Co., Ltd. | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| Tetraphase Pharmaceuticals Inc. | 31 | 1 |
| TiGenix NV | 32 | 1 |
| Community Acquired Pneumonia Therapeutics Assessment | 33 | 9 |
| Assessment by Monotherapy Products | 33 | 1 |
| Assessment by Target | 34 | 2 |
| Assessment by Mechanism of Action | 36 | 2 |
| Assessment by Route of Administration | 38 | 2 |
| Assessment by Molecule Type | 40 | 2 |
| Drug Profiles | 42 | 55 |
| BT-086 Drug Profile | 42 | 1 |
| C-10 Drug Profile | 43 | 1 |
| CAL-02 Drug Profile | 44 | 1 |
| ceftaroline fosamil Drug Profile | 45 | 3 |
| Cx-611 Drug Profile | 48 | 4 |
| DBAF-301 Drug Profile | 52 | 1 |
| delafloxacin Drug Profile | 53 | 8 |
| IFX-1 Drug Profile | 61 | 2 |
| KRPAM-1977X Drug Profile | 63 | 2 |
| KRPAM-1977Y Drug Profile | 65 | 1 |
| lefamulin acetate Drug Profile | 66 | 3 |
| nemonoxacin Drug Profile | 69 | 3 |
| omadacycline tosylate Drug Profile | 72 | 6 |
| PneumoMab Drug Profile | 78 | 1 |
| radezolid Drug Profile | 79 | 3 |
| Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia Drug Profile | 82 | 1 |
| solithromycin Drug Profile | 83 | 10 |
| tosatoxumab Drug Profile | 93 | 2 |
| TP-271 Drug Profile | 95 | 2 |
| Community Acquired Pneumonia Dormant Projects | 97 | 1 |
| Community Acquired Pneumonia Discontinued Products | 98 | 1 |
| Community Acquired Pneumonia Product Development Milestones | 99 | 11 |
| Featured News &Press Releases | 99 | 1 |
| Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia | 99 | 1 |
| Jun 20, 2016: Nabriva Presents Data on Lefamulin at the American Society of Microbiology Microbe 2016 Conference | 99 | 1 |
| Jun 16, 2016: Cempra to Host Analyst and Investor Day on June 23, 2016 | 100 | 1 |
| Jun 14, 2016: Melinta Therapeutics Presenting Results From Baxdela Programs At ASM Microbe 2016 Meeting | 100 | 1 |
| Jun 13, 2016: TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn (nemonoxacin) | 101 | 1 |
| Jun 10, 2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference | 101 | 1 |
| May 31, 2016: Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients | 102 | 1 |
| May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation) | 103 | 1 |
| May 16, 2016: Nabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference | 104 | 1 |
| May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016 | 105 | 1 |
| May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia | 105 | 1 |
| Apr 11, 2016: Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin ( LEAP 2 ) in Patients with Community-Acquired Bacterial Pneumonia | 106 | 1 |
| Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID | 107 | 1 |
| Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets | 107 | 1 |
| Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia | 108 | 2 |
| Appendix | 110 | 2 |
| Methodology | 110 | 1 |
| Coverage | 110 | 1 |
| Secondary Research | 110 | 1 |
| Primary Research | 110 | 1 |
| Expert Panel Validation | 110 | 1 |
| Contact Us | 110 | 1 |
| Disclaimer | 111 | 1 |